NCT02644369进行中（未招募）2 期
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Changes in genomic and immune biomarkers that will be measured in blood and tumor pre-treatment, on-treatment and at progression (progression biopsies only done for those who have complete or partial responses, or stable disease for more than 4 months)
研究概览
简要总结
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment.
Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.
详细描述
This study will involve treatment with pembrolizumab, tests and procedures done for safety, and the collection of archival tumor tissue, fresh tumor biopsies, and blood samples for biomarker research (including genetic testing).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be willing and able to provide written informed consent/assent for the trial.
- •Be 18 years of age or older on day of signing informed consent.
- •Have histologically or cytologically-documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the patient and treating physician. There is no limit to the number of prior treatment regimens.
- •Have one of the following advanced (unresectable and/or metastatic) solid tumor indications:
- •Squamous cell cancer of head and neck
- •Triple negative breast cancer
- •Epithelial ovarian cancer
- •Malignant melanoma
- •Advanced solid tumors
- •Have measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.
- •Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Patients for whom newly-obtained samples cannot be provided (e.g. inaccessible or patient safety concern) will not be eligible for this study.
- •Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
- •Demonstrate adequate organ function.
- •Negative pregnancy test for female patients of childbearing potential.
- •Must use approved methods of birth control during the course of the study and for 120 days after the last dose of study drug.
排除标准
- •Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •Has a known history of active TB (Bacillus Tuberculosis).
- •Hypersensitivity to pembrolizumab or any of its excipients.
- •Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered from adverse events due to agents administered more than 4 weeks earlier.
- •Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or who has not recovered from adverse events due to a previously administered agent.
- •Has a known additional malignancy that is progressing or requires active treatment.
- •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Has active autoimmune disease that has required systemic treatment in the past 2 years
- •Has known history of, or any evidence of active, non-infectious pneumonitis.
- •Has an active infection requiring systemic therapy.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with screening visit through 120 days after the last dose of trial treatment.
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- •Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- •Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
- •Has received a live vaccine within 30 days of planned start of study therapy.
研究组 & 干预措施
Pembrolizumab
Experimental
Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
干预措施: Pembrolizumab (Biological)
结局指标
主要结局
Changes in genomic and immune biomarkers that will be measured in blood and tumor pre-treatment, on-treatment and at progression (progression biopsies only done for those who have complete or partial responses, or stable disease for more than 4 months)
时间窗: 5 years
T-test or Wilcoxon's test
次要结局
- Comparison of baseline tumor RNA expression profile for immune inhibitory genes with clinical outcome (response)(5 years)
- Changes in immune cell subsets in the blood and tumor microenvironment(5 years)
- Distribution of drug tumor penetration using a mass spectrometry assay(5 years)
- Overall response rate(5 years)
- Positive predictive value and negative predictive value of in vitro predictive assay for Pembrolizumab response(5 years)
- Baseline tumor RNA expression profile for immune inhibitory genes(5 years)
- Changes in circulating tumor DNA genomic biomarkers(5 years)
- Changes in radiomic imaging parameters(5 years)
- Correlation between tumor genomic profiles and radiomic imaging signatures(5 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
早期 1 期
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersGynecologic NeoplasmsUterine Endometrial CancerFallopian Tube CancerPeritoneal CancerEpithelial Ovarian CancerNCT02728830AA Secord39
进行中（未招募）
2 期
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaAdrenocortical CarcinomaNCT02673333Memorial Sloan Kettering Cancer Center39
招募中
早期 1 期
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerNCT05493566Emory University15
已完成
2 期
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyStage I Bladder Cancer AJCC v8Stage II Bladder Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage IIIB Bladder Cancer AJCC v8NCT03319745M.D. Anderson Cancer Center23
已完成
2 期
Pembrolizumab +/- Bevacizumab for Recurrent GBMGlioblastomaNCT02337491Dana-Farber Cancer Institute80